Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312302 | 0.88 | SLC6A4 (0.46) | SLC6A4SLC6A2TACR1SLC6A3HTR2C | |
| SCHEMBL7306627 | 0.85 | ALDH1A1 (0.45) | SLC6A4SLC6A2SLC6A3HTR2CGAA | |
| SCHEMBL6605312 | 0.81 | HTR2C (0.47) | SLC6A4SLC6A2SLC6A3HTR2CGAA | |
| SCHEMBL9164261 | 0.80 | TACR1 (0.53) | SLC6A4SLC6A2TACR1SLC6A3 | |
| SCHEMBL7265728 | 0.78 | TACR1 (0.52) | SLC6A4SLC6A2TACR1SLC6A3 | |
| SCHEMBL9159859 | 0.78 | TACR1 (0.52) | SLC6A4SLC6A2TACR1SLC6A3 | |
| SCHEMBL9164273 | 0.77 | TACR1 (0.51) | SLC6A4SLC6A2TACR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL9161808 | 0.77 | TACR1 (0.51) | SLC6A4SLC6A2TACR1SLC6A3 | |
| SCHEMBL23780011 | 0.77 | CTSL (0.42) | SLC6A4SLC6A2SLC6A3HTR2CGAA | |
| SCHEMBL6019029 | 0.77 | CTSL (0.42) | SLC6A4SLC6A2SLC6A3HTR2CGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | SLC6A4 1913/4885SLC6A2 2094/4885TACR1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.